Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-05

AUTHORS

C. Goetz, P. Riva, G. Poepperl, F.J. Gildehaus, A. Hischa, K. Tatsch, H.-J. Reulen

ABSTRACT

Prognosis of malignant glioma is very unfavourable mainly due to minimal tumour remnants in the peritumoural tissue. Intralesionally applied radioimmunotherapy is a possible therapeutical option with the potential to improve survival of patients with malignant glioma. We investigated side effects and survival after surgery, conventional radiotherapy and additional radioimmunotherapy with labelled tenascin-antibodies in patients with malignant glioma.Methods: Since 1995, 37 patients were treated with radioimmunotherapy after resection and radiotherapy of a malignant glioma. Patients received antibodies labelled with yttrium-90 and iodine-131 in different doses into the tumour cavity via a previously implanted ommaya-reservoir. Treatment was applied in up to 8 cycles (mean 2.96 cycles) in time intervals of 6–8 weeks. Mean age was 46 years, histology was anaplastic astrocytoma in 13 patients and glioblastoma in 24 patients.Results: For the whole group median survival time has not yet been reached. For glioblastoma the median survival time is 17 months, 5-year survival probability for anaplastic astrocytoma is 85% approximately. Quality of life was acceptable. Acute side effects following treatment were headache, seizures and worsening of pre-existing neurological symptoms. Late side effects were skin necrosis and, in 1 case, a delayed aphasia probably due to a vascular lesion.Conclusion: Radioimmunotherapy prolonged survival time in a selected group of patients with malignant gliomas as compared to a historical control group. Patients with anaplastic astrocytomas seem to have more benefit from this therapy than patients with glioblastomas. More... »

PAGES

321-328

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1023309927635

DOI

http://dx.doi.org/10.1023/a:1023309927635

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043723074

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12777085


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Radiation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoconjugates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iodine Radioisotopes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radioimmunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tenascin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Distribution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Yttrium Radioisotopes", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goetz", 
        "givenName": "C.", 
        "id": "sg:person.01177702773.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177702773.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Servizio di medicina nucleare, Ospedale Maurizio Bufalini, Cesena, Italien", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Servizio di medicina nucleare, Ospedale Maurizio Bufalini, Cesena, Italien"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Riva", 
        "givenName": "P.", 
        "id": "sg:person.01177547630.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177547630.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poepperl", 
        "givenName": "G.", 
        "id": "sg:person.01272264470.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272264470.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gildehaus", 
        "givenName": "F.J.", 
        "id": "sg:person.01030135266.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030135266.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hischa", 
        "givenName": "A.", 
        "id": "sg:person.01217702663.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217702663.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tatsch", 
        "givenName": "K.", 
        "id": "sg:person.01203226043.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203226043.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reulen", 
        "givenName": "H.-J.", 
        "id": "sg:person.01167043552.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167043552.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf03032361", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038705499", 
          "https://doi.org/10.1007/bf03032361"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01052668", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020515683", 
          "https://doi.org/10.1007/bf01052668"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s004320000188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012351779", 
          "https://doi.org/10.1007/s004320000188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00177479", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015648301", 
          "https://doi.org/10.1007/bf00177479"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-85039-4_15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011103427", 
          "https://doi.org/10.1007/978-3-642-85039-4_15"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590050549", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010084610", 
          "https://doi.org/10.1007/s002590050549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1005952925378", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019014245", 
          "https://doi.org/10.1023/a:1005952925378"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006331416283", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014237854", 
          "https://doi.org/10.1023/a:1006331416283"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2003-05", 
    "datePublishedReg": "2003-05-01", 
    "description": "Prognosis of malignant glioma is very unfavourable mainly due to minimal tumour remnants in the peritumoural tissue. Intralesionally applied radioimmunotherapy is a possible therapeutical option with the potential to improve survival of patients with malignant glioma. We investigated side effects and survival after surgery, conventional radiotherapy and additional radioimmunotherapy with labelled tenascin-antibodies in patients with malignant glioma.Methods: Since 1995, 37 patients were treated with radioimmunotherapy after resection and radiotherapy of a malignant glioma. Patients received antibodies labelled with yttrium-90 and iodine-131 in different doses into the tumour cavity via a previously implanted ommaya-reservoir. Treatment was applied in up to 8 cycles (mean 2.96 cycles) in time intervals of 6\u20138 weeks. Mean age was 46 years, histology was anaplastic astrocytoma in 13 patients and glioblastoma in 24 patients.Results: For the whole group median survival time has not yet been reached. For glioblastoma the median survival time is 17 months, 5-year survival probability for anaplastic astrocytoma is 85% approximately. Quality of life was acceptable. Acute side effects following treatment were headache, seizures and worsening of pre-existing neurological symptoms. Late side effects were skin necrosis and, in 1 case, a delayed aphasia probably due to a vascular lesion.Conclusion: Radioimmunotherapy prolonged survival time in a selected group of patients with malignant gliomas as compared to a historical control group. Patients with anaplastic astrocytomas seem to have more benefit from this therapy than patients with glioblastomas.", 
    "genre": "article", 
    "id": "sg:pub.10.1023/a:1023309927635", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "62"
      }
    ], 
    "keywords": [
      "median survival time", 
      "malignant gliomas", 
      "survival time", 
      "side effects", 
      "anaplastic astrocytoma", 
      "pre-existing neurological symptoms", 
      "survival of patients", 
      "acute side effects", 
      "late side effects", 
      "group of patients", 
      "historical control group", 
      "quality of life", 
      "additional radioimmunotherapy", 
      "locoregional radioimmunotherapy", 
      "Ommaya reservoir", 
      "neurological symptoms", 
      "skin necrosis", 
      "mean age", 
      "therapeutical options", 
      "vascular lesions", 
      "tumor remnants", 
      "tumor cavity", 
      "conventional radiotherapy", 
      "peritumoural tissue", 
      "patients", 
      "control group", 
      "yttrium-90", 
      "tenascin antibodies", 
      "radioimmunotherapy", 
      "gliomas", 
      "iodine-131", 
      "different doses", 
      "astrocytomas", 
      "glioblastoma", 
      "radiotherapy", 
      "survival", 
      "treatment", 
      "survival probability", 
      "resection", 
      "prognosis", 
      "surgery", 
      "group", 
      "seizures", 
      "therapy", 
      "histology", 
      "worsening", 
      "symptoms", 
      "lesions", 
      "necrosis", 
      "doses", 
      "weeks", 
      "months", 
      "antibodies", 
      "time interval", 
      "more benefits", 
      "age", 
      "effect", 
      "tissue", 
      "aphasia", 
      "options", 
      "years", 
      "intervals", 
      "time", 
      "cases", 
      "life", 
      "benefits", 
      "cavity", 
      "experience", 
      "remnants", 
      "quality", 
      "potential", 
      "cycle", 
      "probability"
    ], 
    "name": "Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times", 
    "pagination": "321-328", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043723074"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1023309927635"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12777085"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1023309927635", 
      "https://app.dimensions.ai/details/publication/pub.1043723074"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_375.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1023/a:1023309927635"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1023309927635'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1023309927635'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1023309927635'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1023309927635'


 

This table displays all metadata directly associated to this object as RDF triples.

286 TRIPLES      22 PREDICATES      126 URIs      110 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1023309927635 schema:about N01f4b79398b74326a50adf5194e08ce6
2 N07237381c47845b4a5287229e2ecd727
3 N0efe2f05341a4f51a2a32c3615be269e
4 N27e3924a792f4a4db958a5beb13d59e0
5 N2e05410a07684addbbca9bb174cfbcb9
6 N4f12a549643a4813a92cbfde9ba5750b
7 N52176bfba17146dca1abceeccb857d91
8 N5c99826fd3d145d88ff54f975541ad5b
9 N83da4e850f6044ad87aa391f2dc66cca
10 N8e3535d706594a4bbbd9850f7932fac4
11 N99ccc7e540d94a4f9924c266dcc79b7f
12 Na013abc6bfbc4460addc65cf3589f746
13 Nac79aa14fd854fbb8cd17df0a74f3d97
14 Nd37a106b9b4f43eda695d0c65dff4585
15 Ndcb2bdddd06445cba4bf4366097d725b
16 Ndd63cc2fb5924771897f470347d4da6b
17 Ne838e55bc421438bb5e4ee3851850e9a
18 Nf58b7d8c227a4b0093ee61f0c9af81a5
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author Ndc0e39164f0f48f6befda4654eb8a85a
22 schema:citation sg:pub.10.1007/978-3-642-85039-4_15
23 sg:pub.10.1007/bf00177479
24 sg:pub.10.1007/bf01052668
25 sg:pub.10.1007/bf03032361
26 sg:pub.10.1007/s002590050549
27 sg:pub.10.1007/s004320000188
28 sg:pub.10.1023/a:1005952925378
29 sg:pub.10.1023/a:1006331416283
30 schema:datePublished 2003-05
31 schema:datePublishedReg 2003-05-01
32 schema:description Prognosis of malignant glioma is very unfavourable mainly due to minimal tumour remnants in the peritumoural tissue. Intralesionally applied radioimmunotherapy is a possible therapeutical option with the potential to improve survival of patients with malignant glioma. We investigated side effects and survival after surgery, conventional radiotherapy and additional radioimmunotherapy with labelled tenascin-antibodies in patients with malignant glioma.Methods: Since 1995, 37 patients were treated with radioimmunotherapy after resection and radiotherapy of a malignant glioma. Patients received antibodies labelled with yttrium-90 and iodine-131 in different doses into the tumour cavity via a previously implanted ommaya-reservoir. Treatment was applied in up to 8 cycles (mean 2.96 cycles) in time intervals of 6–8 weeks. Mean age was 46 years, histology was anaplastic astrocytoma in 13 patients and glioblastoma in 24 patients.Results: For the whole group median survival time has not yet been reached. For glioblastoma the median survival time is 17 months, 5-year survival probability for anaplastic astrocytoma is 85% approximately. Quality of life was acceptable. Acute side effects following treatment were headache, seizures and worsening of pre-existing neurological symptoms. Late side effects were skin necrosis and, in 1 case, a delayed aphasia probably due to a vascular lesion.Conclusion: Radioimmunotherapy prolonged survival time in a selected group of patients with malignant gliomas as compared to a historical control group. Patients with anaplastic astrocytomas seem to have more benefit from this therapy than patients with glioblastomas.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf N81385b4d5cd14e83bf25f7218b34fabc
37 N99a375eeb4c0472cbfa69c4270f79b5b
38 sg:journal.1094205
39 schema:keywords Ommaya reservoir
40 acute side effects
41 additional radioimmunotherapy
42 age
43 anaplastic astrocytoma
44 antibodies
45 aphasia
46 astrocytomas
47 benefits
48 cases
49 cavity
50 control group
51 conventional radiotherapy
52 cycle
53 different doses
54 doses
55 effect
56 experience
57 glioblastoma
58 gliomas
59 group
60 group of patients
61 histology
62 historical control group
63 intervals
64 iodine-131
65 late side effects
66 lesions
67 life
68 locoregional radioimmunotherapy
69 malignant gliomas
70 mean age
71 median survival time
72 months
73 more benefits
74 necrosis
75 neurological symptoms
76 options
77 patients
78 peritumoural tissue
79 potential
80 pre-existing neurological symptoms
81 probability
82 prognosis
83 quality
84 quality of life
85 radioimmunotherapy
86 radiotherapy
87 remnants
88 resection
89 seizures
90 side effects
91 skin necrosis
92 surgery
93 survival
94 survival of patients
95 survival probability
96 survival time
97 symptoms
98 tenascin antibodies
99 therapeutical options
100 therapy
101 time
102 time interval
103 tissue
104 treatment
105 tumor cavity
106 tumor remnants
107 vascular lesions
108 weeks
109 worsening
110 years
111 yttrium-90
112 schema:name Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times
113 schema:pagination 321-328
114 schema:productId N22e748cfd90347bb8c63a55cf205da3d
115 N3344fc425d194958aa2fc157eefea3ab
116 Ndd4057afcd13495e930731899aaed231
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043723074
118 https://doi.org/10.1023/a:1023309927635
119 schema:sdDatePublished 2022-05-20T07:22
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher N72cfea2f353f44e9a8f6230e2cd6ce87
122 schema:url https://doi.org/10.1023/a:1023309927635
123 sgo:license sg:explorer/license/
124 sgo:sdDataset articles
125 rdf:type schema:ScholarlyArticle
126 N01f4b79398b74326a50adf5194e08ce6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Iodine Radioisotopes
128 rdf:type schema:DefinedTerm
129 N0292a169f1d648a8a3aea848331bd0c7 rdf:first sg:person.01203226043.77
130 rdf:rest Nc6aa5341acfb4655a4436131b2f56914
131 N07237381c47845b4a5287229e2ecd727 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Tissue Distribution
133 rdf:type schema:DefinedTerm
134 N0efe2f05341a4f51a2a32c3615be269e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Quality of Life
136 rdf:type schema:DefinedTerm
137 N22e748cfd90347bb8c63a55cf205da3d schema:name pubmed_id
138 schema:value 12777085
139 rdf:type schema:PropertyValue
140 N27e3924a792f4a4db958a5beb13d59e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Prognosis
142 rdf:type schema:DefinedTerm
143 N2e05410a07684addbbca9bb174cfbcb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Combined Modality Therapy
145 rdf:type schema:DefinedTerm
146 N3344fc425d194958aa2fc157eefea3ab schema:name doi
147 schema:value 10.1023/a:1023309927635
148 rdf:type schema:PropertyValue
149 N3d4fbfeefa194afe8d1f35b0c2fb2575 rdf:first sg:person.01217702663.99
150 rdf:rest N0292a169f1d648a8a3aea848331bd0c7
151 N4f12a549643a4813a92cbfde9ba5750b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Female
153 rdf:type schema:DefinedTerm
154 N51753f07fc714efb9d349fbd90905523 rdf:first sg:person.01030135266.67
155 rdf:rest N3d4fbfeefa194afe8d1f35b0c2fb2575
156 N52176bfba17146dca1abceeccb857d91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Glioma
158 rdf:type schema:DefinedTerm
159 N5b197ad1d33d4431b70c5c592feecdc2 rdf:first sg:person.01177547630.17
160 rdf:rest N68d468a3016945c09976c2211d8835e4
161 N5c99826fd3d145d88ff54f975541ad5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Dose-Response Relationship, Radiation
163 rdf:type schema:DefinedTerm
164 N68d468a3016945c09976c2211d8835e4 rdf:first sg:person.01272264470.83
165 rdf:rest N51753f07fc714efb9d349fbd90905523
166 N72cfea2f353f44e9a8f6230e2cd6ce87 schema:name Springer Nature - SN SciGraph project
167 rdf:type schema:Organization
168 N81385b4d5cd14e83bf25f7218b34fabc schema:issueNumber 3
169 rdf:type schema:PublicationIssue
170 N83da4e850f6044ad87aa391f2dc66cca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Yttrium Radioisotopes
172 rdf:type schema:DefinedTerm
173 N8e3535d706594a4bbbd9850f7932fac4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Middle Aged
175 rdf:type schema:DefinedTerm
176 N99a375eeb4c0472cbfa69c4270f79b5b schema:volumeNumber 62
177 rdf:type schema:PublicationVolume
178 N99ccc7e540d94a4f9924c266dcc79b7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Aged
180 rdf:type schema:DefinedTerm
181 Na013abc6bfbc4460addc65cf3589f746 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Adult
183 rdf:type schema:DefinedTerm
184 Nac79aa14fd854fbb8cd17df0a74f3d97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Radioimmunotherapy
186 rdf:type schema:DefinedTerm
187 Nc6aa5341acfb4655a4436131b2f56914 rdf:first sg:person.01167043552.60
188 rdf:rest rdf:nil
189 Nd37a106b9b4f43eda695d0c65dff4585 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Humans
191 rdf:type schema:DefinedTerm
192 Ndc0e39164f0f48f6befda4654eb8a85a rdf:first sg:person.01177702773.68
193 rdf:rest N5b197ad1d33d4431b70c5c592feecdc2
194 Ndcb2bdddd06445cba4bf4366097d725b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Tenascin
196 rdf:type schema:DefinedTerm
197 Ndd4057afcd13495e930731899aaed231 schema:name dimensions_id
198 schema:value pub.1043723074
199 rdf:type schema:PropertyValue
200 Ndd63cc2fb5924771897f470347d4da6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Survival Rate
202 rdf:type schema:DefinedTerm
203 Ne838e55bc421438bb5e4ee3851850e9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Immunoconjugates
205 rdf:type schema:DefinedTerm
206 Nf58b7d8c227a4b0093ee61f0c9af81a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Brain Neoplasms
208 rdf:type schema:DefinedTerm
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
213 schema:name Oncology and Carcinogenesis
214 rdf:type schema:DefinedTerm
215 sg:journal.1094205 schema:issn 0167-594X
216 1573-7373
217 schema:name Journal of Neuro-Oncology
218 schema:publisher Springer Nature
219 rdf:type schema:Periodical
220 sg:person.01030135266.67 schema:affiliation grid-institutes:grid.5252.0
221 schema:familyName Gildehaus
222 schema:givenName F.J.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030135266.67
224 rdf:type schema:Person
225 sg:person.01167043552.60 schema:affiliation grid-institutes:grid.5252.0
226 schema:familyName Reulen
227 schema:givenName H.-J.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167043552.60
229 rdf:type schema:Person
230 sg:person.01177547630.17 schema:affiliation grid-institutes:None
231 schema:familyName Riva
232 schema:givenName P.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177547630.17
234 rdf:type schema:Person
235 sg:person.01177702773.68 schema:affiliation grid-institutes:grid.5252.0
236 schema:familyName Goetz
237 schema:givenName C.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177702773.68
239 rdf:type schema:Person
240 sg:person.01203226043.77 schema:affiliation grid-institutes:grid.5252.0
241 schema:familyName Tatsch
242 schema:givenName K.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203226043.77
244 rdf:type schema:Person
245 sg:person.01217702663.99 schema:affiliation grid-institutes:grid.5252.0
246 schema:familyName Hischa
247 schema:givenName A.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217702663.99
249 rdf:type schema:Person
250 sg:person.01272264470.83 schema:affiliation grid-institutes:grid.5252.0
251 schema:familyName Poepperl
252 schema:givenName G.
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272264470.83
254 rdf:type schema:Person
255 sg:pub.10.1007/978-3-642-85039-4_15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011103427
256 https://doi.org/10.1007/978-3-642-85039-4_15
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/bf00177479 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015648301
259 https://doi.org/10.1007/bf00177479
260 rdf:type schema:CreativeWork
261 sg:pub.10.1007/bf01052668 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020515683
262 https://doi.org/10.1007/bf01052668
263 rdf:type schema:CreativeWork
264 sg:pub.10.1007/bf03032361 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038705499
265 https://doi.org/10.1007/bf03032361
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/s002590050549 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010084610
268 https://doi.org/10.1007/s002590050549
269 rdf:type schema:CreativeWork
270 sg:pub.10.1007/s004320000188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012351779
271 https://doi.org/10.1007/s004320000188
272 rdf:type schema:CreativeWork
273 sg:pub.10.1023/a:1005952925378 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019014245
274 https://doi.org/10.1023/a:1005952925378
275 rdf:type schema:CreativeWork
276 sg:pub.10.1023/a:1006331416283 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014237854
277 https://doi.org/10.1023/a:1006331416283
278 rdf:type schema:CreativeWork
279 grid-institutes:None schema:alternateName Servizio di medicina nucleare, Ospedale Maurizio Bufalini, Cesena, Italien
280 schema:name Servizio di medicina nucleare, Ospedale Maurizio Bufalini, Cesena, Italien
281 rdf:type schema:Organization
282 grid-institutes:grid.5252.0 schema:alternateName Klinik und Poliklinik für Nuklearmedizin der, Ludwig-Maximilians-Universität, München, Germany
283 Neurochirurgische Klinik der, Ludwig-Maximilians-Universität, München, Germany
284 schema:name Klinik und Poliklinik für Nuklearmedizin der, Ludwig-Maximilians-Universität, München, Germany
285 Neurochirurgische Klinik der, Ludwig-Maximilians-Universität, München, Germany
286 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...